Bellerophon_banner_home_v2_d3

Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

Bellerophon announces positive data from the final analysis of the phase 2, long-term extension trial of INOpulse for the treatment of Pulmonary Arterial Hypertension (PAH)

To view the press release, click here

Bellerophon announces enrollment of the first patient in the INOvation-1 Phase 3 clinical trial for Pulmonary Arterial Hypertension (PAH)

To view the press release, click here

More About Us

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary arterial hypertension (PAH), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF).